Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. News
  7. Summary
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exagen Inc. Provides Revenue Guidance the Full Year 2021

11/10/2021 | 04:06pm EST

Exagen Inc. provided revenue guidance the full year 2021. For the period, the company reaffirms its prior guidance and expects revenue to be in the range of $47 million to $49 million.


ę S&P Capital IQ 2021
All news about EXAGEN INC.
01/10EXAGEN INC. : Regulation FD Disclosure (form 8-K)
AQ
01/10Exagen, Queen Mary University to Collaborate on Molecular Signatures for Rheumatoid Art..
MT
01/09Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collabor..
AQ
01/09Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collabor..
CI
2021Exagen Inc. to Participate in the Piper Sandler 33rdáAnnual Virtual Healthcare Conferen..
GL
2021Exagen Inc. to Participate in the Piper Sandler 33rdáAnnual Virtual Healthcare Conferen..
GL
2021KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating
MT
2021EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021Exagen Inc. Reports Third Quarter 2021 Results - Form 8-K
PU
2021Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.3M, vs. Street Est of $12.1M
MT
More news
Analyst Recommendations on EXAGEN INC.
More recommendations
Financials (USD)
Sales 2021 47,3 M - -
Net income 2021 -27,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,81x
Yield 2021 -
Capitalization 136 M 136 M -
Capi. / Sales 2021 2,87x
Capi. / Sales 2022 2,42x
Nbr of Employees 182
Free-Float 55,4%
Chart EXAGEN INC.
Duration : Period :
Exagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXAGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 8,39 $
Average target price 24,20 $
Spread / Average Target 188%
EPS Revisions
Managers and Directors
Fortunato Ron Rocca President, Chief Executive Officer & Director
Kamal Adawi Chief Financial Officer & Secretary
Brian P. Birk Chairman
Debra Jeske Zack Chief Medical Officer
Anja Kammesheidt Chief Scientific Officer
Sector and Competitors